Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in severe, life threatening metabolic disorders. The Company’s lead product candidate is setmelanotide, a potent, first in class melanocortin 4 receptor, or MC4R, agonist peptide for the treatment of rare genetic disorders of obesity. Rhythm’s development efforts are initially focused on obesity related to six single gene related, or monogenic, MC4 pathway deficiencies—pro opiomelanocortin, or POMC, leptin receptor, or LEPR, Bardet Biedl syndrome, Alström syndrome, POMC heterozygous, and POMC epigenetic disorders—for which there are currently no effective or approved treatments.